COTELLIC (Cobimetinib) Approved In Combination For BRAF V600+ Metastatic Melanoma, Available Immediately Biologics, Inc. (NC)

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., is pleased to announce that it has been selected by Genentech as a specialty pharmacy provider for COTELLIC (cobimetinib). COTELLIC was granted priority review, and approved by the U.S. Food and Drug Administration on November 10, 2015, to be used in combination with ZELBORAF (vemurafenib) for the treatment of BRAF V600+ metastatic melanoma.

“We’re very pleased to have been selected by Genentech, and to support the launch of this important therapy”

Recognized for its high-touch patient care model, Biologics’ Oncology Pharmacy Services and Patient Access Services group provides a dedicated, clinically relevant team to support the clinical, financial and emotional needs of specific patient populations.

“We’re very pleased to have been selected by Genentech, and to support the launch of this important therapy,” said Shayne Malone, Vice President, Biopharma Services at Biologics. “We believe our high-touch approach to patient care will make a positive impact in our patients’ treatment journey and support better outcomes.”

Biologics’ Oncology Pharmacy Services are designed to support patients needing complex oral, intravenous and self-injectable oncology therapies that require advanced clinical oncology support and prompt resolution of financial barriers.

In 2014, Biologics’ team secured over $29M in copay assistance on behalf of cancer patients. Care plans are developed according to each individual patient profile. According to the latest independent survey, 96% of patients reported they had an exceptional overall experience with Biologics.

Physicians may submit prescriptions to Biologics via phone (800.850.4306, option 2), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

• Pharmacy name: Biologics
• Street address: 120 Weston Oaks Court, Cary, NC 27513
• NCPDP: 3430369
• NPI: 1487640314

About Biologics: Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities, while providing clinical outcomes and informatics reporting that allow for informed decision making. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. Visit biologicsinc.com or follow us on Twitter (@BiologicsInc).